

**ACME PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019**

ACME PHARMA LTD
Unaudited Financial Statements
For The Year Ended 31 March 2019

Contents

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

ACME PHARMA LTD
Balance Sheet
As at 31 March 2019

Registered number: 8999695

		2019		2018	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible Assets	3		460,712		436,141
			460,712		436,141
CURRENT ASSETS					
Debtors	5	326,246		297,316	
Cash at bank and in hand		1,028,793		371,689	
		1,355,039		669,005	
Creditors: Amounts Falling Due Within One Year	6	(898,288)		(355,424)	
NET CURRENT ASSETS (LIABILITIES)			456,751		313,581
TOTAL ASSETS LESS CURRENT LIABILITIES			917,463		749,722
Creditors: Amounts Falling Due After More Than One Year	7		(460,721)		(483,715)
NET ASSETS			456,742		266,007
CAPITAL AND RESERVES					
Called up share capital	8		10		10
Profit and Loss Account			456,732		265,997
SHAREHOLDERS' FUNDS			456,742		266,007

ACME PHARMA LTD
Balance Sheet (continued)
As at 31 March 2019

For the year ending 31 March 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities

- The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
- The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Ms RINKLE BUDDHADEV

27/02/2019

The notes on pages 3 to 6 form part of these financial statements.

ACME PHARMA LTD
Notes to the Financial Statements
For The Year Ended 31 March 2019

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

1.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold	0
Fixtures & Fittings	25
Computer Equipment	25

1.4. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

1.5. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

ACME PHARMA LTD
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2019

1.6. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

2. Average Number of Employees

Average number of employees, including directors, during the year was as follows:

	2019	2018
Office and administration	1	1
Sales, marketing and distribution	5	3
	<u>6</u>	<u>4</u>

ACME PHARMA LTD
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2019

3. Tangible Assets

	Land & Property		
	Freehold	Computer Equipment	Total
	£	£	£
Cost			
As at 1 April 2018	430,110	9,998	440,108
Additions	14,478	16,790	31,268
As at 31 March 2019	<u>444,588</u>	<u>26,788</u>	<u>471,376</u>
Depreciation			
As at 1 April 2018	-	3,967	3,967
Provided during the period	-	6,697	6,697
As at 31 March 2019	<u>-</u>	<u>10,664</u>	<u>10,664</u>
Net Book Value			
As at 31 March 2019	<u>444,588</u>	<u>16,124</u>	<u>460,712</u>
As at 1 April 2018	<u>430,110</u>	<u>6,031</u>	<u>436,141</u>

4. Stocks

2019	2018
£	£
<u> </u>	<u> </u>

5. Debtors

	2019	2018
	£	£
Due within one year		
Trade debtors	233,820	78,386
Other debtors (1)	64,532	64,532
Other debtors (2)	-	50
Rent Deposit	5,627	5,627
VAT	22,021	148,721
Other taxes and social security	246	-
	<u>326,246</u>	<u>297,316</u>

ACME PHARMA LTD
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2019

6. Creditors: Amounts Falling Due Within One Year

	2019	2018
	£	£
Trade creditors	651,397	335,122
Bank loans and overdrafts	2,529	-
Corporation tax	55,860	15,360
Other taxes and social security	-	96
Net wages	3,032	3,032
Pension Fund	272	58
SMART CURRENCY	(259)	(259)
Other creditors (9)	182,692	-
Accruals and deferred income	2,765	2,015
	<u>898,288</u>	<u>355,424</u>

7. Creditors: Amounts Falling Due After More Than One Year

	2019	2018
	£	£
Bank loans	260,721	283,715
Directors loan account	200,000	200,000
	<u>460,721</u>	<u>483,715</u>

Directors Loan is from Ms Rinkle Rameshkumar Buddhadev. The loan is interest free unsecured and subordinated in favour of third party creditors

8. Share Capital

	2019	2018
Allotted, Called up and fully paid	<u>10</u>	<u>10</u>

9. General Information

ACME PHARMA LTD is a private company, limited by shares, incorporated in England & Wales, registered number 8999695. The registered office is 337, ATHLON ROAD, WEMBLEY, HA0 1EF.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.